Dawnrays Pharmaceutical (Holdings) Limited 東瑞製葯(控股)有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註册成立之有限公司） （Stock Code 股份代號：2348） NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s)(Note 1) , 各位非登記股東 （附註1） ： 東瑞製葯(控股)有限公司（「本公司」） — 2025中期報告之刊發通知（「本次公司通訊」） 12 September 2025 Dawnrays Pharmaceutical (Holdings) Limited (the "Company") - Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corpora ...

Dawnrays Pharmaceutical (Holdings) Limited 東瑞製葯(控股)有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註册成立之有限公司） （Stock Code 股份代號：2348） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, Dawnrays Pharmaceutical (Holdings) Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") Yours faithfully, Dawnrays Pharmaceutical (Holdings) Limited Li Kei Ling Chairman Note: Corporate Communications include any document(s) issued or to be is ...

2025 INTERIM REPORT 中期報告 | | Contents | | --- | --- | | | 目錄 | | Corporate Information | 2 | | 公司資料 | | | Group Structure | 4 | | 本集團架構圖 | | | Financial Highlights | 5 | | 財務摘要 | | | Management Discussion and Analysis | 6 | | 管理層討論及分析 | | | Other Information | 20 | | 其他資料 | | | Condensed Consolidated Statement of Profit or Loss | 27 | | 簡明綜合損益表 | | | Condensed Consolidated Statement of Comprehensive Income | 28 | | 簡明綜合全面收益表 | | | Condensed Consolidated Statement of Financial Position | 29 | | 簡明綜合財務狀況表 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東瑞製葯(控股)有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | 東瑞製葯(控股)有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | 本月底法定 ...

Core Viewpoint - Dongrui Pharmaceutical (02348) reported a mid-year performance for 2025, showing a revenue of approximately 630 million, a year-on-year increase of 9.2%, but a significant decline in net profit attributable to shareholders by 78.79% [1] Financial Performance - Revenue reached approximately 630 million, reflecting a year-on-year growth of 9.2% [1] - Gross profit was about 314 million, representing a year-on-year decrease of 7.1% [1] - Net profit attributable to shareholders was approximately 105 million, down 78.79% year-on-year [1] - Earnings per share stood at 0.06961, with an interim dividend of 0.015 HKD per share [1] Product Performance - Sales volume of the hypertension treatment "An" series decreased by 5.7%, with sales revenue declining by 22.1%, primarily due to price reductions in certain regions influenced by national procurement policies [1] - Sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, with sales revenue growing by 8.7% [1] - The product series focused on treating hyperlipidemia in Fujian saw a sales volume increase of 19.5% and sales revenue growth of 16.6% [1] - Sales volume of cephalosporin powder injection grew by 47.9%, with sales revenue increasing by 55.7% [1] - Sales volume of intermediates and raw materials increased by 244.8%, with sales revenue rising by 142.7%, attributed to the commercialization of the Suzhou Dongrui and Lanzhou Dongrui facilities [1] Challenges - The decline in profit was mainly due to the lack of large-scale commercial production at the Suzhou Dongrui and Lanzhou Dongrui facilities, price reductions of the "An" series products in certain provinces due to national policies, and increased R&D expenses [1]

格隆汇8月22日丨东瑞制药(02348.HK)发布公告，截至2025年6月30日止六个月，实现收入人民币6.30亿 元，同比增加9.2%；毛利为人民币3.14亿元，同比减少7.1%；母公司拥有人应占本期间溢利(撇除2024 年非经常性溢利包括出售联营公司收益及设备验证补助)为人民币1.05亿元，同比减少17.1%；母公司拥 有人应占溢利为人民币1.05亿元，同比减少78.8%；基本每股盈利人民币0.06961元，拟派中期股息每股 港币0.015元。本期间溢利下降主要是苏州东瑞善丰路厂区和兰州东瑞未形成规模化的商业化生 产、"安"系列等集采品种受国家政策影响部分省份价格下降以及研发费用增加所致。 ...

Core Insights - Dongrui Pharmaceutical (02348) reported a mid-year performance for 2025, with revenue of approximately 630 million, representing a year-on-year increase of 9.2% [1] - Gross profit was approximately 314 million, showing a year-on-year decrease of 7.1% [1] - Profit attributable to the parent company was approximately 105 million, a significant year-on-year decrease of 78.79% [1] - Earnings per share were 0.06961, with an interim dividend of 0.015 HKD per share [1] Revenue Breakdown - Sales volume of the hypertension treatment "An" series decreased by 5.7%, with sales revenue declining by 22.1%, primarily due to price reductions in certain regions influenced by national procurement policies [1] - Sales volume of the antiviral drug Entecavir dispersible tablets increased by 14.0%, with sales revenue growing by 8.7% [1] - The product series focused on treating hyperlipidemia in Fujian saw a sales volume increase of 19.5% and a sales revenue increase of 16.6% [1] - Sales volume of cephalosporin powder injection increased by 47.9%, with sales revenue rising by 55.7% [1] Production and Operational Insights - With the commercial production of the Suzhou Dongrui Pharmaceutical Co., Ltd. and Lanzhou Dongrui Pharmaceutical Co., Ltd. facilities, the sales volume of intermediates and raw materials increased by 244.8%, and sales revenue grew by 142.7% compared to the same period in 2024 [1] - The decline in profit during this period was attributed to the lack of large-scale commercial production at the Suzhou and Lanzhou facilities, price reductions of "An" series products due to national policies in certain provinces, and increased R&D expenses [1]

EF001 EF001 其他信息 其他信息 不適用 發行人董事 於本公佈刊發之日，本公司董事會成員包括二名執行董事李其玲女士及熊融禮先生；兩名非執行董事梁康民先生及胡碩先生；三名 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 免責聲明 獨立非執行董事勞同聲先生、EDE，Ronald Hao Xi先生及林明儀女士。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 東瑞製葯(控股)有限公司 | | 股份代號 | 02348 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月之中期股息及暫停辦理股份過户登記手續 | | 公告日期 | 2025年8月22日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不對因本公佈全部或任何部份內容而產生或因依賴該等內容而引致之任何損失承擔任何 責任。 DAWNRAYS PHARMACEUTICAL（HOLDINGS）LIMITED 東瑞製葯（控股）有限公司* （在開曼群島註冊成立的有限公司） （股份代號：2348） 截至二零二五年六月三十日止六個月之中期業績公佈 截至二零二五年六月三十日止六個月之中期業績 東瑞製葯（控股）有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此提呈本公司及其 附屬公司（統稱「本集團」）截至二零二五年六月三十日止六個月（「本期間」）之未經審核綜合中期 業績，連同二零二四年同期的比較數字。此等中期業績已經由本公司的審核委員會審閱。 財務摘要 | | 截至六月三十日止六個月 | | | | --- | --- | --- | --- | | 未經審核 | 二零二五年 | 二零二四年 | 變動 | | 收入（人民幣千元） | 630,424 | 577,447 | 9.2% | | 毛利（人民幣千元） | 313,978 ...

Core Viewpoint - Dongrui Pharmaceutical (02348.HK) announced that it will hold a board meeting on August 22, 2025, to consider and approve the interim results for the six months ending June 30, 2025, and to discuss the potential declaration of an interim dividend, if any [1] Group 1 - The board meeting is scheduled for August 22, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The company will also consider the declaration of an interim dividend during the meeting [1]